Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
Drugmaker Celgene reports second-quarter adjusted earnings and revenue that beat analysts' forecasts and raises its guidance through the remainder of the year amid strong sales of its cancer and other disease-fighting treatments.
Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Shareholders of Mylan would get around 40% of the newly formed business and Pfizer shareholders would get the remaining 60%, according to Reuters.
Here's what you need to know if AstraZeneca's pipeline could affect your portfolio.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.